RNA 📈 Avidity Biosciences - Overview

Avidity Biosciences, Inc. is a biopharmaceutical company that focuses on delivering RNA therapeutics, which have the potential to treat a wide range of diseases. The company's approach involves developing antibody oligonucleotide conjugates (AOCs), a novel class of therapeutics designed to overcome the limitations of traditional RNA therapies. By leveraging the specificity of antibodies and the potency of oligonucleotides, AOCs can selectively target and treat diseases that were previously considered untreatable with RNA therapeutics.

The company's pipeline is centered around treating rare monogenic diseases, with a particular emphasis on muscular dystrophies. Its lead product candidate, AOC 1001, is currently in a phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1, a rare and debilitating muscle disease. Additionally, Avidity Biosciences is developing AOC 1044 for the treatment of Duchenne muscular dystrophy, which is also in a phase 1/2 clinical development trial. Another product in the pipeline, AOC 1020, is being developed to treat facioscapulohumeral muscular dystrophy and is currently in a phase 1/2 clinical trial. These product candidates have the potential to address significant unmet medical needs in the treatment of rare skeletal muscle and cardiac diseases.

Founded in 2012 and headquartered in San Diego, California, Avidity Biosciences, Inc. is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol RNA. The company's common stock is classified under the GICS Sub Industry: Biotechnology, and its ISIN is US05370A1088. With a strong focus on innovation and a commitment to developing groundbreaking RNA therapeutics, Avidity Biosciences is poised to make a meaningful impact in the biopharmaceutical industry. For more information, investors and stakeholders can visit the company's website at https://www.aviditybiosciences.com.